We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Inks Licensing, R&D Deal to Bolster Cell Therapy Portfolio
Novartis Inks Licensing, R&D Deal to Bolster Cell Therapy Portfolio
September 6, 2013
Looking to pump up its cell therapy portfolio, Novartis Friday revealed plans to partner with Kentucky-based Regenerex for use of the company’s facilitating cell therapy (FCRx) platform.